#METABOLOMICS WORKBENCH hjyoo2_20200818_181947 DATATRACK_ID:2131 STUDY_ID:ST001467 ANALYSIS_ID:AN002443 PROJECT_ID:PR000999 VERSION 1 CREATED_ON August 27, 2020, 10:02 am #PROJECT PR:PROJECT_TITLE Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation PR:PROJECT_TITLE study PR:PROJECT_SUMMARY A multimodal approach was performed to investigate the effects of BST204 on the PR:PROJECT_SUMMARY alleviation of chemotherapy-induced cachexia. The targeted metabolome changed PR:PROJECT_SUMMARY with chemotheraphy-induced cachexia and the changes were reversed with potential PR:PROJECT_SUMMARY treatment of the cachexia. PR:INSTITUTE Asan medical Center, University of Ulsan College of Medicine PR:LAST_NAME Yoo PR:FIRST_NAME Hyun Ju PR:ADDRESS 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea PR:EMAIL yoohyunju@amc.seoul.kr PR:PHONE 82-02-3010-4029 #STUDY ST:STUDY_TITLE Metabolites changes related to glucose-mediated energy production in ST:STUDY_TITLE chemotheraphy-induced cachexia ST:STUDY_SUMMARY Targeted metabolomics platforms included amino acids and metabolites related to ST:STUDY_SUMMARY glucose-mediated energy production. The targeted metabolome changed with ST:STUDY_SUMMARY chemotheraphy-induced cachexia, and the changes were reversed with potential ST:STUDY_SUMMARY treatment of the cachexia. .rdb files were included as raw data files where ST:STUDY_SUMMARY detailed information regarding MRM transitions and internal standards can be ST:STUDY_SUMMARY found. Several amino acids (Gly, Pro, Gln, Taurine) were analyzed after dilution ST:STUDY_SUMMARY because their peak intensities were too high. Thus their analysis was performed ST:STUDY_SUMMARY separately from other amino acids, and their rdb files were saved in separate ST:STUDY_SUMMARY rdb files. ST:INSTITUTE Asan medical Center, University of Ulsan College of Medicine ST:LAST_NAME Yoo ST:FIRST_NAME Hyun Ju ST:ADDRESS 88, Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, South Korea ST:EMAIL yoohyunju@amc.seoul.kr ST:PHONE 82-02-3010-4029 #SUBJECT SU:SUBJECT_TYPE Mammal SU:SUBJECT_SPECIES Mus musculus SU:TAXONOMY_ID 10090 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data SUBJECT_SAMPLE_FACTORS NTB NTB_1p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_2p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_3p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_4p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_5p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_6p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_1p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_2p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_3p Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_4p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_5p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_6p Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3p Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6p Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_4p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3p Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6p Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=AA_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=AA_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=AA_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_1p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_2p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS NTB NTB_3p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_4p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_5p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_6p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_1p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_2p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_3p_2 Group:batch1 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS TB TB_4p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_5p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS TB TB_6p_2 Group:batch2 | Treatment:Control | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3p_2 Group:batch1 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6p_2 Group:batch2 | Treatment:5FU | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3p_2 Group:batch1 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6p_2 Group:batch2 | Treatment:BST204 | Sample Source:plasma Volume(uL)=50; Weight(mg)=-; RAW_FILE_NAME=Energy metabolism_plasma2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m_2 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m_2 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m_2 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m_2 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m_2 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Energy metabolism_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m_2 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Energy metabolism_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_1m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=27; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_2m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS NTB NTB_3m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_4m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_5m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS NTB NTB_6m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_1m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_2m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_3m_1 Group:batch1 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS TB TB_4m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_5m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS TB TB_6m_1 Group:batch2 | Treatment:Control | Sample Source:muscle Volume(uL)=-; Weight(mg)=31; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_1m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_2m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=32; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_3m_1 Group:batch1 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS 5FU 5FU_4m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=25; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_5m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=23; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS 5FU 5FU_6m_1 Group:batch2 | Treatment:5FU | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_1m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_2m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_3m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST100 BST100_4m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=33; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_5m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=28; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST100 BST100_6m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=34; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_1m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_2m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=29; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_3m_1 Group:batch1 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=26; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle1 SUBJECT_SAMPLE_FACTORS BST200 BST200_4m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_5m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=24; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 SUBJECT_SAMPLE_FACTORS BST200 BST200_6m_1 Group:batch2 | Treatment:BST204 | Sample Source:muscle Volume(uL)=-; Weight(mg)=30; RAW_FILE_NAME=Gly_Pro_Gln_Taurine_muscle2 #COLLECTION CO:COLLECTION_SUMMARY Mice were randomized into five groups (n = 10 each): untreated, CO:COLLECTION_SUMMARY non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); CO:COLLECTION_SUMMARY tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving CO:COLLECTION_SUMMARY 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving CO:COLLECTION_SUMMARY 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells CO:COLLECTION_SUMMARY (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of CO:COLLECTION_SUMMARY phosphate-buffered saline were subcutaneously implanted in the right flank of CO:COLLECTION_SUMMARY 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached CO:COLLECTION_SUMMARY 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was CO:COLLECTION_SUMMARY assigned and drug administration started for 5-FU and BST204 groups. BST204 CO:COLLECTION_SUMMARY (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South CO:COLLECTION_SUMMARY Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 CO:COLLECTION_SUMMARY mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; CO:COLLECTION_SUMMARY 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. CO:COLLECTION_SUMMARY BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: CO:COLLECTION_SUMMARY days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according CO:COLLECTION_SUMMARY to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our CO:COLLECTION_SUMMARY study was determined according to IACUC guidelines, which recommend euthanasia CO:COLLECTION_SUMMARY with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our CO:COLLECTION_SUMMARY study period was limited to day 11. At this point, the change in tumor volumes CO:COLLECTION_SUMMARY was up to 810%, and significant cachexia was observed. CO:SAMPLE_TYPE Blood (plasma) CO:COLLECTION_LOCATION muscle CO:STORAGE_CONDITIONS -20℃ #TREATMENT TR:TREATMENT_SUMMARY Mice were randomized into five groups (n = 10 each): untreated, TR:TREATMENT_SUMMARY non-tumor-bearing mice (NTB group); untreated, tumor-bearing mice (TB group); TR:TREATMENT_SUMMARY tumor-bearing mice receiving 5-FU (5-FU group); tumor-bearing mice receiving TR:TREATMENT_SUMMARY 5-FU and 100-mg/kg BST204 (BST204100 group); and tumor-bearing mice receiving TR:TREATMENT_SUMMARY 5-FU and 200-mg/kg BST204 (BST204200 group). CT26 murine colon carcinoma cells TR:TREATMENT_SUMMARY (1 × 106) (Korean Cell Line Bank, Seoul, Korea) resuspended in 100 μL of TR:TREATMENT_SUMMARY phosphate-buffered saline were subcutaneously implanted in the right flank of TR:TREATMENT_SUMMARY 8-week-old BALB/c mice (Orient Bio, Seongnam, Korea). When tumor volumes reached TR:TREATMENT_SUMMARY 100–200 mm3 (approximately 10 days after tumor cell injection), day 0 was TR:TREATMENT_SUMMARY assigned and drug administration started for 5-FU and BST204 groups. BST204 TR:TREATMENT_SUMMARY (batch number 31037/H1) was obtained from Green Cross Wellbeing (Seongnam, South TR:TREATMENT_SUMMARY Korea), and 5-FU was purchased from Sigma-Aldrich (St. Louis, MO, USA). 5-FU (50 TR:TREATMENT_SUMMARY mg/kg) was injected intraperitoneally in 3-day cycles (1st cycle: days 0–2; TR:TREATMENT_SUMMARY 2nd cycle: days 6–8), in doses that did not exceed the clinically acceptable. TR:TREATMENT_SUMMARY BST204 (100 or 200 mg/kg) was orally administered in 5-day cycles (1st cycle: TR:TREATMENT_SUMMARY days 0–4; 2nd cycle: days 6–10). The BST204 doses were determined according TR:TREATMENT_SUMMARY to its effects on chemotherapy-related fatigue and toxicity. The endpoint of our TR:TREATMENT_SUMMARY study was determined according to IACUC guidelines, which recommend euthanasia TR:TREATMENT_SUMMARY with a maximum tumor volume of 1,500 mm3 and a BW loss of 20%. Therefore, our TR:TREATMENT_SUMMARY study period was limited to day 11. At this point, the change in tumor volumes TR:TREATMENT_SUMMARY was up to 810%, and significant cachexia was observed. TR:TREATMENT 5-FU was injected intraperitoneally in 3-day cycles. BST204 was orally TR:TREATMENT administerd in 5-day cycles. TR:TREATMENT_DOSE 5-FU (50 mg/kg), BST204 (100 or 200 mg/kg) TR:ANIMAL_ENDP_EUTHANASIA study period was limited by day 11 TR:TREATMENT_COMPOUND 5-FU, BST204 #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Metabolites related to glucose-mediated energy metabolism were extracted using SP:SAMPLEPREP_SUMMARY LLE. Amino acids and bioamines were also extracted using LLE and underwent SP:SAMPLEPREP_SUMMARY chemical derivatization with phenylisothiocyante. SP:PROCESSING_STORAGE_CONDITIONS 4℃ SP:EXTRACTION_METHOD Liquid Liquid Extraction (LLE) #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Amino acids and bioamines were analyzed with LC-MS/MS (MRM) CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Agilent 1290 CH:COLUMN_NAME Zorbax Eclipse XDB-C18 (100 x 2mm) CH:FLOW_GRADIENT 0% B for 0.5 min, 0% to 95% B for 5 min, hold at 95% B for 1 min, 95% to 0% B CH:FLOW_GRADIENT for 0.5 min, then hold at 0% B for 2.5 min CH:FLOW_RATE 500 μL/min CH:COLUMN_TEMPERATURE 50 CH:SOLVENT_A 0.2% formic acid in H2O CH:SOLVENT_B 0.2% formic acid in ACN CH:INTERNAL_STANDARD 13C5-glutamine, serotonine-d4, dopamine-d4, tryptophan-d5, serine-d3, and CH:INTERNAL_STANDARD lysine-d8 CH:SAMPLE_INJECTION 3 uL #ANALYSIS AN:ANALYSIS_TYPE MS AN:ACQUISITION_DATE 2018 May #MS MS:INSTRUMENT_NAME ABI Sciex 5500 QTrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:MS_COMMENTS Amino acids and bioamines MRM mode Analyst 1.52 #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS uL(plasma), pmole/mg (muscle) MS_METABOLITE_DATA_START Samples NTB_1p NTB_2p NTB_3p NTB_4p NTB_5p NTB_6p TB_1p TB_2p TB_3p TB_4p TB_5p TB_6p 5FU_1p 5FU_2p 5FU_3p 5FU_4p 5FU_5p 5FU_6p BST100_1p BST100_2p BST100_3p BST100_4p BST100_5p BST100_6p BST200_1p BST200_2p BST200_3p BST200_4p BST200_5p BST200_6p NTB_1m NTB_2m NTB_3m NTB_4m NTB_5m NTB_6m TB_1m TB_2m TB_3m TB_4m TB_5m TB_6m 5FU_1m 5FU_2m 5FU_3m 5FU_4m 5FU_5m 5FU_6m BST100_1m BST100_2m BST100_3m BST100_4m BST100_5m BST100_6m BST200_1m BST200_2m BST200_3m BST200_4m BST200_5m BST200_6m Factors Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch2 | Treatment:Control | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch2 | Treatment:5FU | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch2 | Treatment:BST204 | Sample Source:plasma Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch2 | Treatment:Control | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch2 | Treatment:5FU | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch1 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle Group:batch2 | Treatment:BST204 | Sample Source:muscle L-Alanine 734 713 406 768 397 434 476 360 405 505 377 575 444 418 369 210 265 278 483 277 222 507 688 633 478 403 642 569 532 773 34.3 45.5 18.1 34.3 24 13.6 13.3 17 19.6 21.4 20.1 19.2 29.1 28.8 24.5 21.7 27 22.6 19.2 17.3 19.2 23.6 18.7 19.9 17.1 24.7 34.8 17.6 21.6 20.7 L-Arginine 24 31 29.4 24.6 29.2 30.6 49.1 42.4 38.6 50.4 33.5 44.5 43.5 41.5 31.2 41.9 19.6 24 30.8 19.1 25.3 24.7 45.3 31.9 20.6 27.85 44.7 29.3 21.6 39.9 2.9 3.4 0.6 0.9 0.9 0.7 2.3 1.8 1.9 1.5 1.6 1.9 1.6 1.1 2.1 1.7 1.8 1.3 1.4 2.5 2.5 1.4 1 1.2 2.9 1.8 2.6 2.4 1.7 1.5 D-Asparagine 113 102 77.2 75.5 99.7 64.3 101 88 72.2 84.9 68.1 100 107.5 158 106 108 95.1 71.5 90 80.7 50.2 53.7 59.7 65.2 70.4 72.9 70.55 72 91.9 77.2 3.4 5.7 1.5 2.9 2.8 1.3 2 2.1 1.5 1.7 1.7 1.5 4.5 4.4 2.9 3.2 3.6 3.1 2.8 1.3 2.1 3.5 2.5 1.6 3.4 3.1 3 3.1 2.8 1.5 L-Aspartic acid 7.76 9 6.01 7.37 8.14 6.87 17 17.7 17.8 16.4 21.5 15.8 12.55 17.9 11.9 19.8 10.7 19.1 11.9 4.86 6.39 10.2 16.9 17.3 9.35 12.75 13.7 11.6 15.8 13.1 4.4 5 1.1 3.2 4.1 2.2 2.2 2.1 1.8 1.8 2 1.9 3.4 1.9 3.6 3.1 3.4 2.6 3.2 1.9 2.3 2.7 3.1 2.6 4 3.2 2.4 4.6 3.3 2.3 L-Glutamine 337 360 323 319 346 436 410 447 363 418 457 413 418 372 357 336 394 356 352 285 350 322 474 313 338 508 552 288 472 404 59.3 52.3 43.9 85 53.4 48.9 48.8 50.8 40.3 48.2 46.2 46.8 77.2 68.4 39.3 31 68 66.5 37.1 35.1 38.7 38.9 29.9 49.7 61.4 109 55.8 46 55.4 88 Glycine 70.9 125 53.8 82.4 103 49.4 83.5 92.8 91.3 84 129 87.4 64.6 81.2 82.3 43.9 62.6 33.9 87.4 26.5 37.2 14.4 56.2 30.1 36.1 70.3 78.25 70.1 58 56.8 207 153.2 98.2 101 115.3 61.1 41.9 49.6 16.6 35.3 39.3 41.3 34.4 19.8 64.4 21.1 37.4 39 16.3 31.5 54 22.5 16.7 73.8 37.2 30.9 25.6 23.9 40 35.3 Histamine 0.0422 0.111 0.0484 0.0477 0.0586 0.0593 0.0604 0.0509 0.0538 0.0529 0.0625 0.0479 0.0788 0.0728 0.102 0.0861 0.0608 0.0878 0.0405 0.0301 0.0421 0.0338 0.0424 0.0211 0.0571 0.05115 0.0413 0.0294 0.0497 0.0789 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.4 0.2 0.4 0.3 0.3 0.2 0.2 0.4 0.3 0.4 0.3 0.3 0.4 0.3 0.4 0.4 0.3 L-Histidine 51.6 58.7 72.8 57 46.8 57.9 43.9 58 55.7 45.4 55.8 48.2 87.15 94.4 69 36.6 59.8 36.7 44.5 72.1 56.5 52.9 36 32.3 55.5 45.7 51.2 36.7 58.9 56.3 6.1 7.4 3.4 5.6 4.8 3.5 3.4 3.6 4.5 4.3 4.4 4.1 5.3 5.7 6.1 7.1 6.7 5.7 4.9 4.8 4.3 5.4 5.5 4.8 4.1 6.5 6.9 6.3 7.2 5.9 L-Isoleucine 437 540 490 419 422 467 490 414 505 452 414 525 455 368 584 384 430 465 563 578 419 291 572 314 378 347 355 313 349 449 1.7 2.3 1 2 2.3 1.7 1.1 1.2 1.2 1.4 1.5 2.2 3.4 2.8 2.2 3.5 4.2 3.8 1.3 0.8 1.5 2.7 2 1.1 2.4 2.2 1.5 2.2 2.4 1.3 L-Kynurenine 1.44 1.92 1.5 1.46 1.75 1.76 1.47 2.04 2.11 1.93 1.88 2.48 4.38 2.315 3.63 2.49 2.96 4.29 2.37 2.56 1.89 1.88 3.9 2.3 2.31 2.43 1.885 2.37 2.43 1.65 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 L-Leucine 1160 940 1160 1220 833 1180 905 801 963 920 1190 913 1190 791 1360 892 1420 1320 1130 1490 1030 580 1370 1010 719 677 986 765 641 909 3.6 4.8 2.9 3.9 4.9 3.3 2.5 2.5 2.7 2.7 3.4 3.8 7.9 5.8 5 7.7 9 8.5 3.2 1.7 3.5 5.5 4.9 2.5 6.4 5.4 3.1 5.2 5.5 3.9 L-Methionine 3590 4640 5500 3870 3230 4130 4680 2380 3770 3300 3900 4980 2680 2305 2680 2630 2210 2490 4230 3880 2080 2580 2210 3350 2750 2535 3440 3030 3160 2840 74.4 101.6 61.8 129.3 82.5 66.1 37.5 46.8 38.9 63.6 57.2 66.8 93.4 63.8 76.8 139.2 144.1 203.3 44.2 41.8 67.7 96.1 114.3 112.8 68.3 54.1 32.4 124.2 149.2 108 Methionine sulfoxide 1240 1430 897 564 786 935 1580 885 1240 730 1680 972 2930 1300 2380 2540 1170 2040 1570 1760 635 544 362 1190 1100 1161 976 650 1420 1390 17.1 30 20.5 17.6 26.4 13.4 16 15.8 14 15.8 18.7 30.4 72.8 36.6 58.8 50 49.3 75 16 14.5 19 29.6 24.8 40.3 22.7 12.2 10 24.6 46.3 26 L-Proline 12.8 12.4 7.43 17.5 17.2 9.57 16.3 10.4 14.2 16.7 21 18.8 21.1 14.4 14.8 15.4 8.56 12.5 22.3 17.5 5.16 9.86 24.2 17.4 10.4 17.4 19.7 14.3 11.5 18.9 7.7 5.9 4.6 5.8 4.1 4.1 2.8 4.2 2.1 3.9 4.1 4.2 5.9 4.6 6 4 8.7 9.3 2.4 4 5.5 2.1 3.9 3.9 7.1 3 4.3 4.3 4.4 7.6 L-Phenylalanine 193 165 177 148 124 164 171 142 147 150 119 192 162.5 297 239 182 169 224 208 92.8 153 81 203 121 159 129 129 152 109 166 0.8 0.9 0.8 0.9 1.1 0.7 0.6 0.8 0.7 0.6 0.7 1 1.6 1.3 1.4 2.1 2.1 2.1 0.8 0.6 0.7 1.2 1.1 0.7 1.1 1.1 0.8 1.3 1.4 1.3 L-Serine 87.2 113 96.2 67.8 79.2 54.7 71.6 67.9 68.5 65.5 62.9 61.5 106 84.8 87.4 109 47 49.1 106 74.7 59.9 67.3 52.6 69.8 74.9 81.4 116.45 73.2 62.8 63.7 5.9 9.5 7.8 10.6 6.4 5.8 4.2 5.1 4.3 4.4 5.4 5.2 4.7 5.2 8.4 6.3 7.7 6.5 4.1 4.2 7.3 7.6 7 5.8 5.1 4.7 6.8 9 8.4 6.7 4-Hydroxyproline 5.64 7.59 4.35 6.77 6.08 5.2 6.87 6.96 8.42 5.75 6.82 5.7 2.95 2.345 2.38 3.8 1.49 2.86 5.22 5.96 3.69 3.13 5.22 6.55 3.24 5.32 5.41 3.74 4.36 5.2 4 5.8 2.2 3.3 3 2.3 2.7 1.5 1.6 3 2.2 2.3 0.2 0.4 0.4 0.6 0.2 0.3 1.7 1.9 0.6 0.6 0.4 2.3 1.7 0.9 2.3 0.8 1.4 0.8 L-Threonine 150 150 103 141 123 133 104 111 114 122 149 145 196 186 185 131 142 116 160 149 54 84.2 102 113 120 108.75 132 117 127 156 13 16.5 6.5 10.2 7.8 5.3 6 5.7 6.6 5.3 6.4 5.2 10.1 9 9.6 9.9 10.4 9.4 7.7 8.9 7.2 9.3 7.2 6 9.5 7.5 9.6 8.9 9.3 8 Tryptophan 112 179 119 191 171 229 104 106 107 133 108 174 81.5 105.65 111 109 129 97.7 99.2 124 106 174 141 131 125 144 135.5 145 142 148 1.4 1.7 1.4 1.1 1.1 1.2 1.2 1.1 1.4 1.7 1.4 1.4 1.5 2 1.4 1.9 1.7 1.6 1.4 1.3 1.2 1.6 2.1 1.3 1.5 1.5 1.4 1.9 1.5 2 L-Tyrosine 32.6 32.1 41.2 30.6 34.4 25.6 15.7 13.2 21.1 21.2 13.3 17 19.95 30.2 27.8 19.1 10.5 9.16 17.6 16.7 10.1 7.92 9.75 15.6 12.2 15.35 11.6 12.9 13.4 14 4.6 5.4 1.5 3.4 2.5 1.6 1.3 1.2 1.6 1.2 1 1.6 2.6 1.8 2.2 2.5 2.3 2 1.4 1.4 1.7 1.4 1.9 1.9 1.9 2.1 2.2 2.2 1.9 1.3 L-Valine 3590 2870 3010 2430 2340 2860 2050 2680 2190 2680 2600 2260 3000 1980 2350 2350 2320 3210 3210 1600 2590 1480 3330 2440 1810 2380 2150 1570 2350 2330 10 12.1 8.4 12 12.9 8.9 5.1 7.4 5.6 6.8 7.9 13.3 18.2 12.1 12 17.2 20.9 26.2 7.1 4.2 8.4 13.4 10.5 6.8 11.2 7.9 8.4 11.7 14.2 11.9 MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name KEGG ID Pubchem ID L-Alanine C00041 5950 L-Arginine C00062 6322 D-Asparagine C01905 439600 L-Aspartic acid C00049 5960 L-Glutamine C00064 5961 Glycine C00037 750 Histamine C00388 774 L-Histidine C00135 6274 L-Isoleucine C00407 6306 L-Kynurenine C00328 161166 L-Leucine C00123 6106 L-Methionine C00073 6137 Methionine sulfoxide C02989 847 L-Proline C00148 145742 L-Phenylalanine C00079 6140 L-Serine C00065 5951 4-Hydroxyproline C01157 5810 L-Threonine C00188 6288 Tryptophan C00806 1148 L-Tyrosine C00082 6057 L-Valine C00183 6287 METABOLITES_END #END